Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Wednesday reported positive final Phase 2 immunogenicity and safety results for its Lyme disease vaccine candidate, VLA15.
The study showed strong anamnestic immune responses and antibody levels remaining well above baseline six months after a third yearly booster across all age groups and serotypes.
No safety concerns were identified by the independent Data Monitoring Committee in any age group, confirming a favourable safety profile.
Results support the three-dose primary vaccination schedule with a yearly booster prior to each Lyme season, consistent with the Phase 3 VALOR trial protocol.
Pfizer (NYSE:PFE) and Valneva are collaborating on VLA15's development and commercialisation, with Pfizer planning to submit a Biologics License Application to the FDA and a Marketing Authorisation Application to the EMA in 2026, subject to positive Phase 3 data.
VLA15 remains the most advanced human Lyme disease vaccine candidate, addressing an unmet need in the United States and Europe, where hundreds of thousands of cases are reported annually.
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Inspiring Children Foundation honours NAMI CEO Daniel H Gillison, Jr
AGC Biologics to manufacture AAVantgarde's dual-vector gene therapies for inherited retinal diseases
HitGen signs new funding agreement with Gates Foundation
Nuvalent's zidesamtinib NDA filing accepted by US FDA
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial